Noticeably, while the clinical response rate by RECIST was only slightly higher in BRCA1-associated vs. BRCA1-wildtype BC (Table 1), this difference was significantly more pronounced for pCR (13/24 (54%) vs. 29/192 (15%), p-value < 0.0001; see Table 2). This evidence concerns the gene BRCA1 and breast cancer.